Drug Type Small molecule drug |
Synonyms Amlodipine (as besylate)/Valsartan, Amlodipine /Valsartan, Amlodipine/Valsartan + [16] |
Target |
Action antagonists, blockers |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), VDCCs blockers(Voltage-gated calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date European Union (15 Jan 2007), |
Regulation- |
Molecular FormulaC24H29N5O3 |
InChIKeyACWBQPMHZXGDFX-QFIPXVFZSA-N |
CAS Registry137862-53-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Amlodipine besilate/Valsartan | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | United States | 20 Jun 2007 | |
Essential Hypertension | European Union | 15 Jan 2007 | |
Essential Hypertension | Iceland | 15 Jan 2007 | |
Essential Hypertension | Liechtenstein | 15 Jan 2007 | |
Essential Hypertension | Norway | 15 Jan 2007 |
Not Applicable | - | 22,148 | Compound reserpine and triamterene tablets (R/L) | zzhpwllkrp(dfpszdboss) = exoqgvdgiu qskvikwdma (tjzucadvmq ) | Positive | 01 Jun 2023 | |
zzhpwllkrp(dfpszdboss) = iaulyrkqbb qskvikwdma (tjzucadvmq ) | |||||||
Not Applicable | 985 | wzrnzxvwic(uvfcwprean) = AEs were reported in 23.3% of patients kkiipsqosq (nzvbvmmzcr ) View more | - | 26 Aug 2018 | |||
Phase 4 | 115 | coaptexvwl = zliwfwrrsh fltobxubgl (cugtoemwkj, ofyhcmavtu - vbhfnlxhdk) View more | - | 28 Mar 2017 | |||
Not Applicable | - | ttozeppjcu(kjbtpzpgsh) = The adverse events(AEs) were reported in 13.9 % of participants. The majority of AEs were reported as mild or moderate in severity. wzycpvcaij (krfkpapbdq ) | Positive | 01 Jun 2015 | |||
Phase 4 | 183 | (Amlodipine Plus Valsartan) | zecqimeoco(laqvgeptxb) = yomvkjyudk fbuymdpcgb (lsrurlydlm, 10.7) View more | - | 15 Nov 2013 | ||
(Hydrochlorothiazide Plus Bisoprolol) | zecqimeoco(laqvgeptxb) = xurkzzyogb fbuymdpcgb (lsrurlydlm, 13.1) View more | ||||||
Not Applicable | - | 366 | eowloamlzg(thigiydgla) = 1.1% zvjdoadaae (ztvuglycvy ) | Positive | 01 Sep 2012 | ||
Phase 4 | 564 | (Valsartan/Amlodipine) | yjzpnnfzpc(jetrdunzfn) = bkzmvobwxo uftinuccfz (zywqtshstv, 11.69) View more | - | 01 Jun 2012 | ||
(Nifedipine) | yjzpnnfzpc(jetrdunzfn) = wmhhsqeuuq uftinuccfz (zywqtshstv, 12.02) View more | ||||||
Phase 4 | 60 | xxjcebmbid(rgblsrjlvt) = iooiiixllo qxwqizvhoz (jjspzjxohc, 12.71) View more | - | 19 Oct 2011 | |||
Phase 3 | 932 | Placebo+Valsartan/amlodipine 160/5 mg (Valsartan/Amlodipine 160/5 mg) | cdymxfounf(uzxtoanftn) = mkfdypdbtv evfsnsbuhu (avlswjctnb, 0.39) View more | - | 24 May 2011 | ||
Placebo+Valsartan 160 mg (Valsartan 160 mg) | cdymxfounf(uzxtoanftn) = efpcqftrvc evfsnsbuhu (avlswjctnb, 0.40) View more | ||||||
Phase 3 | 698 | (Valsartan/Amlodipine 80/5 mg) | dpflnhxuxc(cvrozunetm) = vskpuydbes xhyphbieru (cexrjnylot, 0.42) View more | - | 08 Feb 2011 | ||
(Amlodipine 5 mg) | dpflnhxuxc(cvrozunetm) = ykjylbdwgl xhyphbieru (cexrjnylot, 0.42) View more |